Therapeutic targeting of this network at the level of RAC1B and/or PAR2 for inhibition or activation may represent a feasible strategy to enhance TGF-β’s tumor suppressor function or interfere with its malignant effects in fibrosis and tumor progression, respectively. The gene discussed is TGFB1; the disease is neoplasm.